Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study

2
1
Favorite

Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study

T-Reuters2021-06-04

Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

imsomeonelse
·2021-06-05
Goodie
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2140401760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-04 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2140401760","market":"us","top_or_hot":-1,"title":"Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study","media":"T-Reuters","content":"<html><body><p>Gilead Sciences Inc <gild.o>:Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</gild.o></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 23:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>T-Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUP","symbol_name":"Superior Industries International","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2140401760","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140401760","pubTimestamp":1622819067,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Tre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUP":"Superior Industries International","GILD":"吉利德科学","SPN":"Superior Energy Services Inc","SMP":"Standard Motor Products Inc"},"translate_title":"在Ascent三期研究中，Trodelvy在转移性三阴性乳腺癌二线治疗中显示出优于标准护理的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMP":1,"SPN":1,"SUP":1,"GILD":0.9},"content_text":"Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","kind":"highlight","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":112509022,"gmtCreate":1622880334966,"gmtModify":1704192942419,"author":{"id":"3572697049328629","authorId":"3572697049328629","name":"imsomeonelse","avatar":"https://community-static.tradeup.com/news/9294e9e7f11f190688efe808098fa12b","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3572697049328629","authorIdStr":"3572697049328629"},"htmlText":"Goodie","listText":"Goodie","text":"Goodie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112509022","repostId":2140401760,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}